#United States #Needham #Stealth BioTherapeutics #FORZINITY #mitochondrial diseases

Stealth BioTherapeutics Reports Strong Launch of FORZINITY and Pipeline Growth in Mitochondrial Medicine

Introduction

Stealth BioTherapeutics Inc., a pivotal player in biotechnology focused on mitochondrial dysfunction disorders, has recently shared exciting updates regarding its commercial product, FORZINITY (elamipretide). The company is making strides not only in launching this therapy but also in broadening its pipeline of treatments aimed at various rare and age-related mitochondrial diseases.

Overview of FORZINITY Launch

The launch of FORZINITY is an essential milestone for patients diagnosed with Barth syndrome (BTHS), a rare mitochondrial disorder. This specialized injection has been crafted for those weighing at least 30 kg and is part of an ongoing effort to provide innovative therapies to underserved patient populations. According to Reenie McCarthy, CEO of Stealth BioTherapeutics, the initial uptake has been remarkable, indicating strong patient engagement and rapid treatment access. Here are some key highlights from the commercial rollout:

• - Patient Access: As of the latest report, 33 patients have commenced therapy, with an impressive 85% achieving full insurance coverage. This robust adoption rate across various treatment centers signals a positive reception in the medical community.
• - Time to Treatment: The average duration from initial order submission to drug dispensation is under 30 days, showcasing exceptional coordination between physicians, patients, and pharmacies in managing the treatment process.
• - Support Programs: The Mito Assist™ patient support initiative has successfully enrolled 100% of eligible FORZINITY recipients, offering guidance and resources to ensure smooth therapeutic journeys.

Advancements in Research and Development

Stealth BioTherapeutics is equally focused on expanding its research footprint. The company is working closely with the U.S. Food and Drug Administration (FDA) to explore potential label enhancements for BTHS patients outside the current weight eligibility. This entails a new pharmacokinetic study slated for 2026, targeting children under 30 kg. They are also enhancing data collection processes via a proposed registry to inform future FDA evaluations better. In conjunction with ongoing clinical trials, the company has marked the initiation of a Phase 4 trial in Bristol, UK, to gather further evidence of the clinical advantages of FORZINITY.

Furthermore, the company has established direct communication with the FDA regarding regulatory strategies for treatments aimed at POLG-related myopathy, potentially broadening its therapeutic impacts in mitochondrial myopathy cases.

Pipeline Progress

Stealth BioTherapeutics maintains an ambitious pipeline extending beyond BTHS and includes:

• - Dry Age-Related Macular Degeneration (AMD): A Phase 3 trial (ReNEW) assessing elamipretide's effectiveness in treating dry AMD is underway, with encouraging feedback from the FDA suggesting that a single trial could suffice for drug approval.
• - Ongoing Trials: The completion of patient enrollment for a Phase 1 trial concerning bevemipretide eye drops is scheduled, with preliminary findings anticipated soon at the 2026 ARVO Annual Meeting.
• - Broader Initiatives: The company continues to actively participate in collaborations, such as the XPRIZE Healthspan competition, which evaluates elamipretide in functional aging scenarios, and has commenced new research investigating SBT-589’s potential in Leigh syndrome.

Conclusion

The recent developments from Stealth BioTherapeutics highlight significant momentum in both its commercial ventures and research endeavors aimed at mitochondrial diseases. With a potential trajectory that includes label expansions and enriched patient access measures, Stealth is positioned to spearhead advancements in mitochondrial medicine. As they continue to prioritize patient well-being through innovative solutions, the future looks promising for both Stealth BioTherapeutics and the patients they serve.

For further insight into FORZINITY and the company’s plans, interested parties are encouraged to stay updated through their official communications and disclosures.